Tagged with MS

Aspen Labs Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced to open up and diversify, quite simply to have their fingers in as many pies where they can compete successfully.…

Generics Tom Rönnlund discusses the current state of the pharmaceutical industry in the Nordics in this time of austerity, and offers opinions on reference pricing and cooperation in the region. How have the markets in Denmark and Sweden evolves over the past five years, since the financial crisis started and austerity…

Human Resources Teresa Bitetti has a long history with BMS, spanning 3 decades in which she rose up the ranks starting from Senior Director of Abilify Marketing before becoming Sales Vice President of CNS until she reached her current position of President and General Manager of BMS Canada. Today she shares with…

government relations Mike Brogan, before taking up the mantle of President at IMS was VP of Business Integration at IMS for a year. Today, he talks about the difficulties he has come up against since becoming President, especially in government relations and investment. He also offers insights on the future of marketing…

IMS Health Ireland Mr. Egan, what path led you to IMS Health? My original background is in science—I received a PhD in medical microbiology, and worked for some time as a post-doctoral researcher for a Swedish biotech company that was contracting research services here in Ireland. I have since hung up my lab…

Growth Why did MSD decide to have Denmark as the headquarters for the Mid Europe 2 region? This Mid Europe 2 region consists of 10 countries, most of them clustered around the Nordics, which include the Nordics, the Baltics, Switzerland and Austria. The region is characterized by stable economies with positive GDP…

IMSS (Mexican Institute of Social Security) IMSS is a central pillar in the Mexican healthcare system, covering all Mexicans working for the declared formal private sector. How do you assess the quality of the healthcare that is provided by IMSS? To assess the efficiency of our services, it is key to look at the amount of…

MSD In Q3 2012, MSD reported worldwide sales of $11.5 billion. What was the contribution that emerging markets had? From an MSD perspective, emerging markets refer to every market outside North America, Western Europe and Japan. Today, emerging markets contribute to around 18% of MSD’s total revenues. For the next 5…

IMS Health Belgium Looking at your background, we see that you have been with IMS for over 12 years. What defines your loyalty to the company? What appeals most to you about IMS? My loyalty to IMS Health lies in the opportunities I have been presented during all these years. Although I have…

CMS Cameron McKenna Czech Republic Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated pharmaceutical regulatory frameworks in Europe–ensuring, for instance, that market access for drugs can take up to three years longer in…

MSD Belgium It truly seems that you have pharma in your genes, with a father who successfully developed a migraine drug in addition to your 4 years practicing medicine and now continuing an 18 year career with MSD. What distinguishes MSD as a pharmaceutical company in your opinion? At MSD, we are…

MSD Czech Republic Dr. Novotný, in 2008, you became Managing Director for MSD for the Czech and Slovak Republics. In the very next year after your appointment, you were tasked with managing the merger between MSD and Schering-Plough. How challenging was this undertaking, and what were the keys to its success? This was…